BriaCell Therapeutics (TSX:BCT) Change In Payables And Accrued Expense : C$2.29 Mil (TTM As of Jan. 2025)

View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Change In Payables And Accrued Expense?

BriaCell Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Jan. 2025 was C$0.85 Mil. It means BriaCell Therapeutics's Accounts Payable & Accrued Expense increased by C$0.85 Mil from Oct. 2024 to Jan. 2025 .

BriaCell Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Jul. 2024 was C$7.76 Mil. It means BriaCell Therapeutics's Accounts Payable & Accrued Expense increased by C$7.76 Mil from Jul. 2023 to Jul. 2024 .

BriaCell Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for BriaCell Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Change In Payables And Accrued Expense Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

3.93

-2.75

0.50

1.14

7.76

BriaCell Therapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															3.86	3.87	0.96	-3.40	0.85

BriaCell Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jan. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was C$2.29 Mil.

BriaCell Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

BCTX:USA 8BT0:Germany 8BT0:Germany

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Executives

Jamieson Bondarenko	Director
Marc Lustig	10% Security Holder, Director
Gadi Levin	Senior Officer
William Williams	Director, Senior Officer

BriaCell Therapeutics Headlines

No Headlines